Mindmed advances treatment for generalized anxiety disorder

New york, ny, december 18, 2023 – biopharmaceutical company, mind medicine (nasdaq: mnmd) has announced positive results from its phase 2b clinical trial of mm-120 (lysergide d-tartrate) in generalized anxiety disorder (gad). the trial met its primary endpoint, with mm-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements.
MNMD Ratings Summary
MNMD Quant Ranking